|
1
|
Rasalkar DD, Chu WC, Lee V, Paunipagar BK,
Cheng FW and Li CK: Pulmonary metastases in children with
osteosarcoma: Characteristics and impact on patient survival.
Pediatr Radiol. 41:227–236. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li X, Huang T, Jiang G, Gong W, Qian H and
Zou C: Proteasome inhibitor MG132 enhances TRAIL-induced apoptosis
and inhibits invasion of human osteosarcoma OS732 cells. Biochem
Biophys Res Commun. 439:179–186. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Somasekharan SP, Koc M, Morizot A, Micheau
O, Sorensen PH, Gaide O, Andera L and Martinou JC: TRAIL promotes
membrane blebbing, detachment and migration of cells displaying a
dysfunctional intrinsic pathway of apoptosis. Apoptosis.
18:324–336. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ng CP, Zisman A and Bonavida B: Synergy is
achieved by complementation with Apo2L/TRAIL and actinomycin D in
Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: Role of
XIAP in resistance. Prostate. 53:286–299. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gillissen B, Richter A, Richter A,
Overkamp T, Essmann F, Hemmati PG, Preissner R, Belka C and Daniel
PT: Targeted therapy of the XIAP/proteasome pathway overcomes
TRAIL-resistance in carcinoma by switching apoptosis signaling to a
Bax/Bak-independent ‘type I’ mode. Cell Death Dis. 4:e6432013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fakler M, Loeder S, Vogler M, Schneider K,
Jeremias I, Debatin KM and Fulda S: Small molecule XIAP inhibitors
cooperate with TRAIL to induce apoptosis in childhood acute
leukemia cells and overcome Bcl-2-mediated resistance. Blood.
113:1710–1722. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tnah LH, Lee CT, Lee SL, Ng CH and Ng KK:
Development of microsatellites in Labisia pumila (Myrsinaceae), an
economically important Malaysian herb. Appl Plant Sci. 2:pii:
apps.1400019. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ndontsa BL, Tchinda A, Teponno RB, Mpetga
JS, Frédérich M and Tane P: Ardisikivuoside, a new triterpenoid
saponin from Ardisia kivuensis (Myrsinaceae). Nat Prod Commun.
7:515–516. 2012.PubMed/NCBI
|
|
9
|
Karimi E, Jaafar HZ, Aziz MA, Taheri S and
AzadiGonbad R: Genetic relationship among Labisia pumila
(Myrsinaceae) species based on ISSR-PCR. Genet Mol Res.
13:3301–3309. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Allensworth JL, Aird KM, Aldrich AJ,
Batinic-Haberle I and Devi GR: XIAP inhibition and generation of
reactive oxygen species enhances TRAIL sensitivity in inflammatory
breast cancer cells. Mol Cancer Ther. 11:1518–1527. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li X, Huang T, Jiang G, Gong W, Qian H and
Zou C: Synergistic apoptotic effect of crocin and cisplatin on
osteosarcoma cells via caspase induced apoptosis. Toxicol Lett.
221:197–204. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kong Y, Yin J, Cheng D, Kong Y, Yin J,
Cheng D, Lu Z, Wang N, Wang F and Liang M: Antithrombin III
attenuates AKI following acute severe pancreatitis. Shock. Jul
17–2017.(Epub ahead of print).
|
|
13
|
Song F, Wang H and Wang Y: Myeloid
ecotropic viral integration site 1 inhibits cell proliferation,
invasion or migration in human gastric cancer. Oncotarget.
8:90050–90060. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zou J, Zhang W and Li XL: Effects of SOST
gene silencing on proliferation, apoptosis, invasion, and migration
of human osteosarcoma cells through the Wnt/β-catenin signaling
pathway. Calcif Tissue Int. 100:551–564. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mahmood T and Yang PC: Western blot:
Technique, theory, and trouble shooting. N Am J Med Sci. 4:429–434.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lu Z, Cheng D, Yin J, Wu R, Zhang G, Zhao
Q, Wang N, Wang F and Liang M: Antithrombin III protects against
contrast-induced nephropathy. EBioMedicine. 17:101–107. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Moon MH, Jeong JK, Seo JS, Seol JW, Lee
YJ, Xue M, Jackson CJ and Park SY: Bisphosphonate enhances TRAIL
sensitivity to human osteosarcoma cells via death receptor 5
upregulation. Exp Mol Med. 43:138–145. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Srinivasan S, Kumar R, Koduru S,
Chandramouli A and Damodaran C: Inhibiting TNF-mediated signaling:
A novel therapeutic paradigm for androgen independent prostate
cancer. Apoptosis. 15:153–161. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Voelkel-Johnson C: An antibody against DR4
(TRAIL-R1) in combination with doxorubicin selectively kills
malignant but not normal prostate cells. Cancer Biol Ther.
2:283–290. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Newsom-Davis T, Prieske S and Walczak H:
Is TRAIL the holy grail of cancer therapy? Apoptosis. 14:607–623.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mitsiades CS, Treon SP, Mitsiades N, Shima
Y, Richardson P, Schlossman R, Hideshima T and Anderson KC:
TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug
resistance in multiple myeloma: Therapeutic applications. Blood.
98:795–804. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Locklin RM, Federici E, Espina B, Hulley
PA, Russell RG and Edwards CM: Selective targeting of death
receptor 5 circumvents resistance of MG-63 osteosarcoma cells to
TRAIL-induced apoptosis. Mol Cancer Ther. 6:3219–3228. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang WQ, Zhang H, Wang HB, Sun YG, Peng
ZH, Zhou G, Yang SM, Wang RQ and Fang DC: Programmed cell death 4
(PDCD4) enhances the sensitivity of gastric cancer cells to
TRAIL-induced apoptosis by inhibiting the PI3K/Akt signaling
pathway. Mol Diagn Ther. 14:155–161. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
von Pawel J, Harvey JH, Spigel DR, Dediu
M, Reck M, Cebotaru CL, Humphreys RC, Gribbin MJ, Fox NL and
Camidge DR: Phase II trial of mapatumumab, a fully human agonist
monoclonal antibody to tumor necrosis factor-related
apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination
with paclitaxel and carboplatin in patients with advanced
non-small-cell lung cancer. Clin Lung Cancer. 15:188–196.e2. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zheng SJ, Wang P, Tsabary G and Chen YH:
Critical roles of TRAIL in hepatic cell death and hepatic
inflammation. J Clin Invest. 113:58–64. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Garnett TO, Filippova M and
Duerksen-Hughes PJ: Bid is cleaved upstream of caspase-8 activation
during TRAIL-mediated apoptosis in human osteosarcoma cells.
Apoptosis. 12:1299–1315. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang DS, Miao XD, Ye ZM and Xu YS:
Synergistic induction of apoptosis by the combination of TRAIL and
low dose adriamycin in human osteosarcoma cell line U2OS. Zhonghua
Zhong Liu Za Zhi. 27:595–597. 2005.(In Chinese). PubMed/NCBI
|
|
28
|
Wu J, Zeng T, Wu X, Gao Q, Zhai W and Ding
Z: Ether à go-go 1 silencing in combination with TRAIL
overexpression has synergistic antitumor effects on osteosarcoma.
Cancer Biother Radiopharm. 28:65–70. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lanuti P, Bertagnolo V, Pierdomenico L,
Bascelli A, Santavenere E, Alinari L, Capitani S, Miscia S and
Marchisio M: Enhancement of TRAIL cytotoxicity by AG-490 in human
ALL cells is characterized by downregulation of cIAP-1 and cIAP-2
through inhibition of Jak2/Stat3. Cell Res. 19:1079–1089. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ren YG, Wagner KW, Knee DA, Aza-Blanc P,
Nasoff M and Deveraux QL: Differential regulation of the TRAIL
death receptors DR4 and DR5 by the signal recognition particle. Mol
Biol Cell. 15:5064–5074. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Schneider P, Thome M, Burns K, Bodmer JL,
Hofmann K, Kataoka T, Holler N and Tschopp J: TRAIL receptors 1
(DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate
NF-kappaB. Immunity. 7:831–836. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yin D, Wang N, Zhang SL, Jiang Y, Lu YM,
Wei H, Huo NC, Xiao Q and Ou YL: Specific siRNA inhibits XIAP
expression in human endometrial carcinoma cell apoptosis. Cell
Biochem Biophys. 71:161–165. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Poojari R: Embelin-a drug of antiquity:
Shifting the paradigm towards modern medicine. Expert Opin Investig
Drugs. 23:427–444. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cragg GM, Newman DJ and Yang SS: Natural
product extracts of plant and marine origin having antileukemia
potential. The NCI experience. J Nat Prod. 69:488–498. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dai Y, Qiao L, Chan KW, Yang M, Ye J, Ma
J, Zou B, Gu Q, Wang J, Pang R, et al: Peroxisome
proliferator-activated receptor-gamma contributes to the inhibitory
effects of Embelin on colon carcinogenesis. Cancer Res.
69:4776–4783. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hu R, Zhu K, Li Y, Yao K, Zhang R, Wang H,
Yang W and Liu Z: Embelin induces apoptosis through down-regulation
of XIAP in human leukemia cells. Med Oncol. 28:1584–1588. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Marsh JL, Jackman CP, Tang SN, Shankar S
and Srivastava RK: Embelin suppresses pancreatic cancer growth by
modulating tumor immune microenvironment. Front Biosci (Landmark
Ed). 19:113–125. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jiang L, Hao JL, Jin ML, Zhang YG and Wei
P: Effect of Embelin on TRAIL receptor 2 mAb-induced apoptosis of
TRAIL-resistant A549 non-small cell lung cancer cells. Asian Pac J
Cancer Prev. 14:6115–6120. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hu R, Yang Y, Liu Z, Jiang H, Zhu K, Li J
and Xu W: The XIAP inhibitor Embelin enhances TRAIL-induced
apoptosis in human leukemia cells by DR4 and DR5 upregulation.
Tumour Biol. 36:769–777. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lu S, Zhang Z, Chen M, Li C, Liu L and Li
Y: Silibinin inhibits the migration and invasion of human gastric
cancer SGC7901 cells by downregulating MMP-2 and MMP-9 expression
via the p38MAPK signaling pathway. Oncol Lett. 14:7577–7582.
2017.PubMed/NCBI
|
|
41
|
Yang S, Li SS, Yang XM, Yin DH and Wang L:
Embelin prevents LMP1-induced TRAIL resistance via inhibition of
XIAP in nasopharyngeal carcinoma cells. Oncol Lett. 11:4167–4176.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yang T, Lan J, Huang Q, Chen X, Sun X, Liu
X, Yang P, Jin T, Wang S and Mou X: Embelin sensitizes acute
myeloid leukemia cells to TRAIL through XIAP inhibition and NF-κB
inactivation. Cell Biochem Biophys. 71:291–297. 2015. View Article : Google Scholar : PubMed/NCBI
|
